دورية أكاديمية
How Successful Are APRI and FIB-4 Scores in Predicting Liver Fibrosis in Chronic Hepatitis B Patients?
| العنوان: | How Successful Are APRI and FIB-4 Scores in Predicting Liver Fibrosis in Chronic Hepatitis B Patients? |
|---|---|
| المؤلفون: | Gür-Altunay D; Department of Infectious Diseases and Clinical Microbiology, Health Sciences University Van Training and Research Hospital, Van, Türkiye., Yürük-Atasoy P; Department of Infectious Diseases and Clinical Microbiology, Ankara City Hospital, Ankara, Türkiye. |
| المصدر: | Infectious diseases & clinical microbiology [Infect Dis Clin Microbiol] 2023 Dec 29; Vol. 5 (4), pp. 332-340. Date of Electronic Publication: 2023 Dec 29 (Print Publication: 2023). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Doc Design and Informatics Co. Ltd Country of Publication: Turkey NLM ID: 9918680988406676 Publication Model: eCollection Cited Medium: Internet ISSN: 2667-646X (Electronic) Linking ISSN: 2667646X NLM ISO Abbreviation: Infect Dis Clin Microbiol Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: İstanbul, Turkey : Doc Design and Informatics Co. Ltd., [2019]- |
| مستخلص: | Objective: We aimed to evaluate the correlation of fibrosis severity in liver biopsies, the gold standard for the diagnosis of patients with chronic hepatitis B (CHB), using noninvasive methods such as the aspartate aminotransferase (AST)-to-platelet ratio index (APRI) and fibrosis-4 score (FIB-4). Materials and Methods: The study included patients who were followed and treated for CHB in 2018-2023. Biochemical markers and liver biopsy findings of the cases were retrospectively, and their correlations with APRI and FIB-4, which are noninvasive scores, were compared. Results: The study included 202 patients. The biochemical markers and liver biopsy findings of the cases were examined retrospectively, and their correlations with the noninvasive scores APRI and FIB-4 were compared. According to liver biopsy results, 109 (54.0%) cases had no fibrosis (stage 0.1), 85 (42.1%) cases had mild fibrosis (stage 2, 3), and 8 (4%) cases had severe fibrosis (stage 4, 5, 6). The median FIB-4 score was 0.79 (0.25 -11.74), and the median APRI score was 0.29 (0.10-29.40). When the predictive power of the APRI score to discriminate between "without fibrosis" and "with fibrosis (mild and severe)" was evaluated by receiver operating characteristic (ROC) curve analysis, for the APRI score >0.408 as the ideal cut-off point, the sensitivity and specificity were found to be 34% and 79%, respectively. When the cut-off point for the FIB-4 score was >0.701, the sensitivity and specificity were 71% and 46%, respectively. Although the area under the curve (AUC) ratios ranged between 52% and 64% in the ROC analyses, the sensitivity ratios of the cut-off points calculated for FIB-4 were higher. The likelihood ratios of the cut-off point we found for the APRI score (1.61 and 1.75, respectively) were relatively better than those for FIB-4 (1.31 and 1.41, respectively). Conclusion: Noninvasive tests used to detect liver fibrosis in individuals with CHB do not eliminate the need for liver biopsy but may provide insight into the fibrosis status of patients. Competing Interests: The authors declare no conflict of interest. (Copyright © 2024 Infectious Diseases and Clinical Microbiology.) |
| References: | Hepat Mon. 2011 Feb;11(2):103-6. (PMID: 22087126) Ann Clin Biochem. 2005 Nov;42(Pt 6):441-7. (PMID: 16259794) Hepatology. 2005 Dec;42(6):1437-45. (PMID: 16317674) Turk J Gastroenterol. 2014 Aug;25(4):411-5. (PMID: 25254524) Hepatology. 2011 Mar;53(3):726-36. (PMID: 21319189) J Hepatol. 2009 Jan;50(1):36-41. (PMID: 19012989) Ann Intern Med. 2013 Jun 4;158(11):807-20. (PMID: 23732714) Turk J Gastroenterol. 2018 Jul;29(4):464-472. (PMID: 30249562) J Hepatol. 2004 Mar;40(3):501-6. (PMID: 15123366) Sci Rep. 2018 Oct 10;8(1):15074. (PMID: 30305679) J Hepatol. 2021 Sep;75(3):659-689. (PMID: 34166721) Hepatology. 2018 Apr;67(4):1560-1599. (PMID: 29405329) J Hepatol. 2017 Aug;67(2):370-398. (PMID: 28427875) Hepatology. 2006 Jun;43(6):1317-25. (PMID: 16729309) N Engl J Med. 2001 Feb 15;344(7):495-500. (PMID: 11172192) Lancet. 2015 Oct 17;386(10003):1546-55. (PMID: 26231459) Frontline Gastroenterol. 2022 Feb 15;13(5):436-439. (PMID: 36051951) Am J Gastroenterol. 2002 Oct;97(10):2614-8. (PMID: 12385448) Dig Dis. 2014;32(6):791-9. (PMID: 25376298) Am J Gastroenterol. 2005 Mar;100(3):616-23. (PMID: 15743360) Aliment Pharmacol Ther. 2004 Aug 1;20(3):249-59. (PMID: 15274661) J Hepatol. 2015 Jul;63(1):237-64. (PMID: 25911335) Hepatology. 2011 Jun;53(6):1874-82. (PMID: 21360720) |
| فهرسة مساهمة: | Keywords: APRI; FIB-4; chronic hepatitis b; fibrosis; liver biopsy |
| تواريخ الأحداث: | Date Created: 20240418 Latest Revision: 20240419 |
| رمز التحديث: | 20240419 |
| مُعرف محوري في PubMed: | PMC10986711 |
| DOI: | 10.36519/idcm.2023.276 |
| PMID: | 38633858 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2667-646X |
|---|---|
| DOI: | 10.36519/idcm.2023.276 |